Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shanjinlian is a Traditional Chinese Medicine (TCM) formulation developed by Shanxi Yellow River Traditional Chinese Medicine Co., Ltd. for the treatment of the common cold, specifically targeting the Wind-Heat Syndrome (风热证). Formulated as a soft capsule, it is designed to clear heat and detoxify, which are standard therapeutic goals in TCM for viral respiratory infections. The drug has undergone clinical evaluation in China, including dose-finding studies and Phase 3 trials (e.g., CTR20241345) intended to support its registration and production for the relief of cold symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shanjinlian.